T
Entrada Therapeutics D
D
TRDA
4.45000
USD
-0.29
(-6.08%)
Market Open
Last updated: · Delayed 15 min
Volume
13,875
EPS
-4
Div Yield
-
P/E
-1
Market Cap
173,268,177
Title: Entrada Therapeutics
Sector: Healthcare
Industry: Biotechnology
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.